AI Article Synopsis
- - Monoclonal antibodies (mAbs) and the antiviral drug remdesivir show potential as treatments for viral infections, such as those caused by Marburg and Ebola viruses, and SARS-CoV-2.
- - In a study using rhesus monkeys infected with the Marburg virus (MARV), treatments initiated 5 days after infection were effective, but those starting at 6 days resulted in no survival when used alone.
- - The combination of the mAb MR186-YTE and remdesivir started at 6 days post-inoculation provided significant protection (80% survival), indicating that combination therapy could be beneficial for patients with severe filovirus infections.
Article Abstract
Monoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising monotherapies for many viruses, including members of the genera Marburgvirus and Ebolavirus (family Filoviridae), and more recently, SARS-CoV-2. One of the major challenges of acute viral infections is the treatment of advanced disease. Thus, extending the window of therapeutic intervention is critical. Here, we explore the benefit of combination therapy with a mAb and remdesivir in a non-human primate model of Marburg virus (MARV) disease. While rhesus monkeys are protected against lethal infection when treatment with either a human mAb (MR186-YTE; 100%), or remdesivir (80%), is initiated 5 days post-inoculation (dpi) with MARV, no animals survive when either treatment is initiated alone beginning 6 dpi. However, by combining MR186-YTE with remdesivir beginning 6 dpi, significant protection (80%) is achieved, thereby extending the therapeutic window. These results suggest value in exploring combination therapy in patients presenting with advanced filovirus disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994808 | PMC |
| http://dx.doi.org/10.1038/s41467-021-22132-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Study of Intradermal Injection of Non-Crosslinked Sodium Hyaluronate Combined With Human Epidermal Growth Factor in the Treatment of Skin Barrier Injury in Plateau Area.
J Cosmet Dermatol
December 2024
Department of Plastic Surgery, Affiliated Calmette Hospital of Kunming Medical University, Kunming, China.
Background: The Yunnan-Guizhou Plateau's high-altitude setting is characterized by intense solar ultraviolet radiation, a significant environmental stressor that frequently leads to skin barrier damage. This damage presents clinically as erythema, itching, and desquamation, underscoring the need for effective reparative interventions.
Aims: The objective of this study was to assess the therapeutic efficacy of a novel treatment protocol that integrates non-crosslinked hyaluronic acid (HA) injection with microneedle application of human epidermal growth factor (hEGF) for the restoration of skin barrier function in regions of high altitude.
Long-term effects of neoadjuvant chemotherapy in variant histology locally advanced colon cancer: a propensity score-matched analysis.
Cancer Biol Ther
December 2025
Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Purpose: Neoadjuvant chemotherapy (NAC) has proven valuable in treating locally advanced colon cancer (LACC) and is included as a treatment option for patients with clinical T4b colon cancer by the National Comprehensive Cancer Network. However, the long-term survival benefit of NAC in LACC remains debated, due to a lack of conclusive clinical trial results identifying the patients who would benefit most from NAC. This study aimed to assess the efficacy of NAC in patients with LACC based on histological subtype.
View Article and Find Full Text PDFCase report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration.
Front Immunol
December 2024
Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
The STK11 gene mutation is a common genetic alteration in non-small cell lung cancer (NSCLC) and is significantly associated with poor responses to current immunotherapy regimens. Despite its prevalence, there is currently no established standard for front-line treatment in this subtype of NSCLC, underscoring the increasing need for personalized therapeutic strategies. In this report, we present a case of a patient with STK11-mutant NSCLC who was treated with first-line cadonilimab (10mg/kg) in combination with pemetrexed (500mg/m^2) plus carboplatin (AUC=5), resulting in a notable extension of progression-free survival (PFS).
View Article and Find Full Text PDFCase report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma.
Front Immunol
December 2024
The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A 20-year-old Asian male with refractory BL, whose lymphoma had not responded to multiple chemoimmunotherapy regimens, received myeloablative ASCT followed three days later by infusion of a novel third-generation CAR T cells engineered with CD28 and CD3ζ signaling domains, along with a TLR2 costimulatory domain. This resulted in sustained complete remission at the 306-day follow-up, without experiencing any severe complications.
View Article and Find Full Text PDFClinical Efficacy of Tuina Therapy for Acute Lumbar Sprain: A Bayesian Network Meta-Analysis Based on Randomized Controlled Trials.
J Pain Res
December 2024
School of Acupuncture, Tuina and Rehabilitation, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Purpose: Traditional Chinese medicine possesses distinct advantages in the treatment of acute lumbar sprains, and Tuina (Chinese massage) is a commonly employed therapeutic method. This study employed a Bayesian meta-analysis to assess the efficacy and safety of Tuina therapy for acute lumbar sprain with the aim of providing more evidence-based medical substantiation for clinical practice.
Patients And Methods: Randomized controlled trials of Tuina therapy for acute lumbar sprains published in CNKI, CSPD, CCD, CBM, PubMed, Embase, Cochrane Library, and Web of Science were searched up to August 7, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!